Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4560736 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| LY4560736 Part A: Single-Ascending Dose (SAD) | EXPERIMENTAL | LY4560736 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV or SC in healthy volunteers. |
| LY4560736 Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | LY4560736 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid PET scan. |
| Name | Type | Description |
|---|---|---|
| LY4560736 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
| Florbetapir F18 | OTHER | Administered IV |
| Florbetaben F 18 | OTHER | Administered IV |
Inclusion Criteria: * Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study. * To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biologic...
LY4560736 is an investigational small molecule being developed by Eli Lilly and Company. It is in Phase 1 clinical development and is being studied in healthy participants and in participants with Alzheimer's disease. It has not been approved by the FDA and remains an experimental compound.
LY4560736 is being studied for Alzheimer's disease, including participants with amyloid plaque and plasma amyloid measures, alongside healthy volunteers. Because it is in Phase 1 testing, its use is limited to clinical research and it is not available as a treatment.
LY4560736 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants and participants with Alzheimer's disease.
LY4560736 is in Phase 1 clinical development. One Phase 1 trial has been registered and is currently active, with a planned enrollment of 111 participants. The study is randomized, double blind, and placebo controlled, and it has not yet begun recruiting.
LY4560736 is being evaluated in the Phase 1 trial NCT07843459, titled A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease. The trial plans to enroll 111 participants across the United States, China, and Japan, and it is currently not yet recruiting.
The Phase 1 trial NCT07843459 enrolls adults 18 years and older of any sex, including healthy volunteers and participants with Alzheimer's disease. It is a randomized, double blind, placebo controlled study being conducted at sites in the United States, China, and Japan.